文献速递治疗药物监测与药物基因组学特殊人群用药

苗族与东亚人群基于基因型的华法林剂量需求预测差异

Differences in Predicted Warfarin Dosing Requirements Between Hmong and East Asians Using Genotype-Based Dosing Algorithms.
PubMed 文献 · Pharmacotherapy · 2020-12-21

本研究对两个苗族成人队列(n=236和n=198)进行CYP2C9、VKORC1和CYP4F2基因分型,与IWPC东亚人群(n=1165)比较等位基因频率,并预测华法林敏感性和维持剂量。结果显示苗族CYP2C9*3频率显著更高,预测华法林敏感比例更高、平均维持剂量更低。

要点

  • 苗族人群CYP2C9*3等位基因频率显著高于东亚人群(18.9% vs 3.0%)。
  • 苗族预测华法林高敏感比例显著高于东亚人群(28% vs 5%)。
  • 苗族预测华法林平均维持剂量显著低于东亚人群(19.8 vs 21.3 mg/周)。

核心结论

  • 苗族与东亚人群的华法林相关等位基因频率差异结合非遗传因素,导致预测维持剂量需求存在临床相关差异。

研究设计与样本

  • 研究纳入两个独立苗族成人队列(n=236和n=198),对CYP2C9*2、*3、VKORC1 G-1639A和CYP4F2*3进行基因分型。
  • 将合并苗族队列(n=433)与2009年IWPC研究中的东亚人群(n=1165)进行等位基因频率比较。

主要发现

  • 合并苗族队列CYP2C9*3等位基因频率为18.9%,东亚人群为3.0%(p<0.001)。
  • VIP-Hmong队列CYP4F2*3等位基因频率为9.8%,东亚人群为22.1%(p<0.001)。
  • 苗族预测华法林高敏感比例为28%,东亚人群为5%(p<0.01)。
  • 苗族预测华法林平均维持剂量为19.8 mg/周,东亚人群为21.3 mg/周(p<0.001)。

临床怎么用

  • 临床在为苗族患者选择华法林剂量时,应考虑其CYP2C9*3等位基因频率较高及预测维持剂量较低的特点。

局限性

  • 研究基于预测剂量而非实际临床结局,样本量有限,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Warfarin's narrow therapeutic index and high variability in dosage requirements make dosage selection critical. Genetic factors are known to impact warfarin dosage selection. The Hmong are a unique Asian subpopulation numbering over 278,000 in the United States whose participation in genetics-based research is virtually nonexistent. The translational significance of early reports of warfarin pharmacogene differences in Hmong has not been evaluated. OBJECTIVES: (i) To validate previously identified allele frequency differences relevant to warfarin dosing in Hmong versus East Asians and (ii) to compare predicted warfarin sensitivity and maintenance doses between a Hmong population and an East Asian cohort. METHOD: DNA collected from two independent cohorts (n=236 and n=198) of Hmong adults were genotyped for CYP2C9 (*2, *3), VKORC1 (G-1639A), and CYP4F2 (*3). Allele frequencies between the combined Hmong cohort (n=433) and East Asians (n=1165) from the 2009 International Warfarin Pharmacogenetics Consortium (IWPC) study were compared using a χ2 test. Percentages of Hmong and East Asian participants predicted to be very sensitive to warfarin were compared using a χ2 test, and the predicted mean warfarin maintenance dose was compared with a t test. RESULTS: The allele frequencies of CYP2C9*3 in the combined Hmong cohort and CYP4F2*3 in the VIP-Hmong cohort are significantly different from those in East Asians (18.9% vs 3.0%, p<0.001 and 9.8% vs 22.1%, p<0.001, respectively). Comparing the combined Hmong cohort to the East Asian cohort, the percentage of participants predicted to be very sensitive to warfarin was significantly higher (28% vs 5%, p<0.01) and the mean predicted warfarin maintenance dose was significantly lower (19.8 vs 21.3 mg/week, p<0.001), respectively. CONCLUSION: The unique allele frequencies related to warfarin when combined with nongenetic factors observed in the Hmong translate into clinically relevant differences in predicted maintenance dose requirements for Hmong versus East Asians.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Sun B, Wen YF, Culhane-Pera KA, et al. Differences in Predicted Warfarin Dosing Requirements Between Hmong and East Asians Using Genotype-Based Dosing Algorithms. Pharmacotherapy. 2020. PMID: 33202062. doi:10.1002/phar.2487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。